Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir + Ivermectin + Niclosamide for Accelerating Viral Clearance in Mild-to-Moderate COVID-19
TCTR20230403007Phase 2Completed
- Sponsor
- National Health Foundation
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of favipiravir, ivermectin, niclosamide in coronavirus disease 2019 (COVID-19), sponsored by National Health Foundation. Started Dec 2022; status: completed.
02
Drugs
favipiravirivermectinniclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230403007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230403007.